David Seiffge

We’ve just enrolled the 100th patient in the #TECNO trial 💿🎉 A huge thank you to all sites, teams, and patients for making this progress possible 🙏

Dr Gonzalo Valle Peñacoba participated in the ESO Stroke Master’s programme in Bern, and shares his reflections: eso-stroke.org/eso-scholarshi… 📣 Apply now: ow.ly/rQlo50Wghnh #StrokeMedicine #ESO #MAS2024 #MedicalEducation

#FlashbackFriday ! 🌍🧠World Stroke Organization (WSO): Global intracerebral hemorrhage factsheet 2025 journals.sagepub.com/doi/full/10.11… @adrianpj1 @WorldStrokeOrg @WorldStrokeEd

Hear about the evolving role of MRI in diagnosing transient ischemic attacks with our insightful conversation from #ESOC2025 with Dr Philipp Bücke of @unibern.🧠😄 Click here to watch: 🎥 ow.ly/7ZO250W1tig #NeuroTwitter #voiceofstroke #StrokeTwitter

Bonne fête nationale à toutes et tous. Vive la République, vive la France !

Excited to be on Board! TECNO trial!! Great job @inselgruppe @ESOstroke

The new ESO–EANS guideline on intracerebral haemorrhage outlines best practice for acute care, surgery, and blood pressure control. 🔗 Read the guideline: journals.sagepub.com/doi/10.1177/23… #Stroke #ESOC2025 #ICH #VoiceOfStroke #ESOGuidelines @EANSonline50

#MondayTip #PostStrokeMovementDisorders PSMD occur in 1-4% of strokes 🔎Review of 284 cases, frequencies: 🤷‍♀️Dystonia 23% (delayed onset) 👋Chorea 16% (earliest) 🦵Myoclonus 15% 🕸️Weak link between lesion site & PSMD suggests network-level dysfunction doi.org/10.1016/j.jstr…

Nice paper by @Dr_No_Charite @Jan_FriSch et al. from @BerlinStroke @ChariteBerlin ✅ Background. Troponin elevation is common post-stroke, but mechanisms remain unclear 🧠 Population. 508 ischemic stroke patients with serial hs-cTnT in 1st 48h – 254 with acute myocardial…

🧠“It boosts clinical confidence & builds a strong international network.” – Prof. Simon Jung on the European Stroke Master Programme 🔗 Read the interview: eso-stroke.org/european-maste… 🗓 Apply by 31 Aug: eso-stroke.org/resources/euro… #Stroke @MASStroke @inselgruppe @FishingNeurons

This is a breakthrough study that forges a new future — POC biomarkers for identifying #ICH in the prehospital phase. Rapid Diagnosis of ICH with GFAP Levels on a Point-of-Care Device (DETECT) @neurology #curingcoma neurology.org/doi/10.1212/WN…

Many thanks to all the CATALYST collaborators, who helped us to solve this old dilemma in acute stroke management: there is no reason to delay anticoagulants in ischemic stoke patients with atrial fibrillation! @inselgruppe @StrokeBern @unibern

Such research has extraordinary return of investment. Funders need to know, consider and implement.

🎉 Huge congratulations to @DrGargiBanerjee (@MRC_Prion) on receiving a £2m MRC Clinician Scientist Fellowship! Her research will apply prion biology to diseases caused by the amyloid-beta protein to advance our understanding of potential transmission routes. 👉…

🚨 Milestone reached 🚨 We have officially enrolled 50% of the patients in the #TECNO study 💿 Huge thanks to all participating centers, coordinators, and teams for your dedication and teamwork 🙏

Don’t delay DOACs after stroke with AF, global study urges: thelimbus.co.uk/neurology/dont…

🚨 New in @TheLancet: The CATALYST meta-analysis refines when to start anticoagulation after ischaemic stroke in #AF patients. Proud to see major contribution from @StrokeBern driving international stroke research forward! 🧠 sciencedirect.com/science/articl… @FishingNeurons @UCLStrokeRes

Read Prof David Werring’s commentary in @TheLancetNeuro Rapid blood pressure lowering after acute intracerebral haemorrhage: time is brain, again - The Lancet Neurology thelancet.com/journals/laneu…

#MondayTip 📊Pooled INTERACT data ✅Intensive BP lowering improves recovery in ICH ⏱️When started <3h (cutoff: 2.6h)➡️reduces haematoma growth ☝️Greatest benefit in mild–moderate ICH (ICH score) 🚨Early treatment improves outcomes👉supports CODE-ICH systems & future trial design

Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST) - The Lancet thelancet.com/journals/lance…